Maxicold Reno powder for solution for oral administration lemon No. 10

Name:
Maxicold Reno por. d / adj. r-ra d / ingestion lemon in pack. 15g per pack No. 10
Description:
Powder for solution for oral administration (lemon): granulated yellow lemon powder with a specific odor. The presence of white crystals and easily crumbling lumps is allowed. The powder dissolves in 250 ml of hot water to form an opalescent light yellow solution with a characteristic lemon odor. The main active ingredient is PARACETAMOL, PHENYLEFRINE, PHENIRAMINE, ASCORBIC ACID Form of release powder Dosage 15 g Pharmacological properties The combined drug has antipyretic, vasoconstrictive, analgesic and anti-allergic effects. Paracetamol has an antipyretic and analgesic effect: it reduces the pain syndrome observed in “cold” diseases – sore throat, headache, muscle and joint pain, reduces high temperature. Pheniramine maleate has an anti-allergic effect: it reduces swelling and hyperemia of the mucous membranes of the nasal cavity, nasopharynx and paranasal sinuses, reduces runny nose and lacrimation. Phenylephrine hydrochloride has a vasoconstrictive effect: it reduces swelling of the nasopharyngeal mucosa. Ascorbic acid (vitamin C) compensates for the increased need for vitamin C in “colds” and flu, especially in the initial stages of the disease. The combined action of pheniramine and phenylephrine leads to a decrease in nasal congestion and facilitate nasal breathing. Pharmacokinetics Paracetamol is rapidly and completely absorbed from the gastrointestinal tract. Maximum plasma concentrations are observed after 30-60 minutes. At therapeutic doses, the elimination half-life is approximately 1-4 hours. Biotransformation occurs mainly through conjugation reactions in the liver. However, depending on the level of plasma concentration, paracetamol also undergoes partial deacetylation or hydroxylation. Within 24 hours, 90-100% of the applied dose is excreted through the kidneys in the form of glucuronides (60%), sulfates (35%) or cysteine conjugates (3%). The maximum concentration of pheniramine maleate in the blood plasma is reached after 1-2.5 hours. The half-life is 16-19 hours. 70-83% of the oral dose is excreted in the urine unchanged or as metabolites. Phenylephrine has limited bioavailability due to insufficient absorption in the gastrointestinal tract and a presystemic effect in the intestine and liver, which are caused by the action of MAO. Ascorbic acid is easily absorbed from the gastrointestinal tract and widely distributed in body tissues, 25% binds to plasma proteins. Excess ascorbic acid is excreted in the urine. Indications for use Short-term symptomatic treatment of “colds” and influenza, accompanied by high fever, chills, headache, sore throat, sinus pain, nasal congestion, symptoms of acute rhinitis, muscle and joint pain. Dosage and administration Dissolve the contents of one packet in 1 cup of boiled hot water. Consume hot. You can add sugar to taste. A repeat dose can be taken every 4 hours (no more than 3 doses in 24 hours). If there is no relief of symptoms within 3 days after starting the drug, you should consult a doctor. If one or more doses are missed, the drug should be resumed as usual without doubling the dose. Skipping the next dose of the drug If one or more doses are missed, the drug should be resumed as usual, without doubling the dose. Special instructions During treatment, it is not recommended to use drugs that depress the central nervous system (hypnotics, anxiolytics, etc.). It is not recommended to use other anti-cold medicines containing similar active substances at the same time as taking Maxicold Reno. With caution, Maxicold® Rhino should be taken simultaneously with metoclopramide, domperidone, cholestyramine and indirect anticoagulants (warfarin). The drug is not recommended for patients with rare congenital diseases (fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency). In the case of taking the drug by patients on a low sugar diet, it should be borne in mind that each sachet corresponds to 1.0 XE. Do not use the drug from damaged bags. The drug is not recommended for more than 3 days without a doctor’s prescription. Do not exceed the recommended dose. In the absence of a therapeutic effect, it is necessary to stop treatment and consult your doctor. Tell your doctor if you are taking this drug if you are having uric acid and blood sugar tests. Glutathione deficiency due to eating disorders, cystic fibrosis, HIV infection, starvation, malnutrition causes the possibility of developing severe liver damage with small overdoses of paracetamol (5 g or more). Do not take simultaneously with other paracetamol containing agents. If you exceed the recommended doses, contact your doctor immediately, even if you feel well, as there is a risk of delayed serious liver damage. Seek immediate medical attention if you experience an allergic reaction (swelling of the face, mouth, throat, difficulty breathing, itching or rash). There have been reports of cases of serious liver dysfunction after taking paracetamol, including cases of acute liver failure that required liver transplantation or ended in death. Rare cases of anaphylaxis and other hypersensitivity reactions have been reported after taking paracetamol. Influence on the ability to drive vehicles and control mechanisms During treatment, it is not recommended to drive a car or other mechanisms that require concentration of attention and a high speed of psychomotor reactions. Precautions In case of liver or kidney disease, prostatic hyperplasia, you should consult a doctor before taking the drug. In order to avoid toxic damage to the liver, the drug should not be combined with the intake of alcoholic beverages, and should not be taken by persons prone to chronic alcohol consumption. The risk of developing liver damage increases in patients with alcoholic hepatosis. Interaction with other drugs It is recommended to refrain from taking the drug when taking monoamine oxidase inhibitors. The risk of hepatotoxic action of paracetamol increases with the simultaneous administration of barbiturates, diphenin, carbamazepine, rifampicin, zidovudine and other inducers of microsomal liver enzymes. Antidepressants, antiparkinsonian and antipsychotic drugs, phenothiamine derivatives increase the risk of urinary retention, dry mouth, and constipation. Reduces the hypotensive effect of guanethidine, which in turn enhances the alpha-adrenostimulating activity of phenylephrine. The absorption of paracetamol may increase while taking metoclopramide or domperidone, and decrease when taking cholestyramine. Paracetamol reduces the effectiveness of diuretics, uricosuric drugs. Paracetamol increases the effectiveness of indirect anticoagulants. The combined use of phenylephrine with other sympathomimetic amines, tricyclic antidepressants, cardiac glycosides may increase the risk of side effects from the cardiovascular system. Phenylephrine may reduce the effect of beta-blockers and other antihypertensive agents. This increases the risk of side effects from the cardiovascular system. The combined use of phenylephrine with ergot preparations increases the risk of ergotism. The combined use of the drug with glucocorticosteroids increases the risk of developing glaucoma. The simultaneous use of the drug with halothane increases the risk of developing ventricular arrhythmias. Contraindications Hypersensitivity to individual components of the drug, severe hepatic / renal failure, pregnancy, breastfeeding, children’s age (up to 12 years), diseases of the cardiovascular system (severe forms of coronary heart disease, myocardial infarction, unstable angina pectoris, aortic stenosis , severe atherosclerosis, heart rhythm disturbances, decompensated heart failure, uncontrolled arterial hypertension), severe diseases of the thyroid gland (hyperthyroidism), lungs (including bronchial asthma), blood system, pancreas, bladder; peptic ulcer of the stomach and duodenum; difficulty urinating with prostate adenoma; pheochromocytoma; sharing with other sympathomimetic decongestants; use in patients taking or taking the last two weeks monoamine oxidase inhibitors, tricyclic antidepressants or beta-blockers; diabetes; angle-closure glaucoma; deficiency of glucose-6-phosphate dehydrogenase, congenital hyperbilirubinemia (Gilbert, Dubin-Johnson, Rotor syndromes). Do not take concomitantly with other medicines containing paracetamol, decongestants, cold or flu symptoms. Composition One sachet contains: active substances: paracetamol 325 mg, pheniramine maleate 20 mg, phenylephrine hydrochloride 10 mg, ascorbic acid 50 mg; excipients: citric acid, malic acid, sucrose (refined sugar), titanium dioxide E 171, sodium citrate, flavor (citric or orange), dye quinoline yellow E 104, calcium phosphate, ethylcellulose. Overdose In case of exceeding the recommended doses, consult a doctor immediately, even if you feel well, as there is a risk of delayed serious liver damage. An overdose of paracetamol is especially dangerous in elderly patients and in young children. Overdose resulting from incorrect dosing or accidental poisoning can be fatal. Overdose symptoms (nausea, vomiting, anorexia, sweating, pallor of the skin, stomach pain) usually occur within the first 24 hours after taking paracetamol. After 1-2 days, signs of liver damage are determined (pain in the liver, increased activity of “liver” enzymes). Perhaps the development of disorders of carbohydrate metabolism and metabolic acidosis. In adult patients, liver damage develops after taking more than 10 g of paracetamol, in children – when taking more than 125 mg / kg of the child’s body weight. If there are factors that affect the toxicity of paracetamol to the liver (see section “Interaction with other drugs”, “Special instructions”), liver damage is possible after taking 5 or more grams of paracetamol. In severe cases of overdose as a result of liver failure, encephalopathy (impaired brain function), bleeding, hypoglycemia, cerebral edema, and even death may develop. Possible nephrotoxic effect (renal colic, nonspecific bacteriuria, interstitial nephritis, papillary necrosis) up to the development of acute renal failure with acute tubular necrosis, the characteristic features of which are pain in the lumbar region, hematuria (an admixture of blood or red blood cells in the urine). Treatment: if an overdose is suspected, even in the absence of severe symptoms, it is necessary to stop using the drug and urgently take the patient to a hospital for immediate medical attention. If paracetamol was taken orally, gastric lavage may be performed. An assessment of the plasma concentration of paracetamol is necessary, but not earlier than 4 hours after an overdose (earlier results are unreliable). Treatment is symptomatic. The treatment regimen for an overdose of parapecetamol usually includes the appointment as soon as possible (within 24 hours) of the antidote N-acetylcysteine (if necessary, administered intravenously). The maximum protective effect is provided within the first 8 hours after an overdose, over time, the effectiveness of the antidote drops sharply. In the absence of vomiting before the patient enters the hospital, methionine may be used. The need for additional therapeutic measures (further administration of methionine, intravenous administration of acetylcysteine) is determined depending on the concentration of paracetamol in the blood, as well as on the time elapsed after its administration. Treatment of patients with severe liver dysfunction 24 hours after taking paracetamol should be carried out in conjunction with specialists from a poison control center or a specialized department for liver diseases. Side effects Possible allergic reactions (shortness of breath, bronchospasm, sweating, nausea, Quincke’s edema, anaphylactic shock), irritability, decreased rate of psychomotor reactions, fatigue, dry mouth, urinary retention, vomiting, stomach pain, constipation, diarrhea, flatulence, palpitations, increased blood pressure, dizziness, sleep disturbance, mydriasis, paresis of accommodation, increased intraocular pressure, headache and bradycardia (due to the symptomatic effect of phenylephrine). Sometimes children have anxiety and insomnia. Given the presence of paracetamol: rarely – disorders of the blood system (anemia, thrombocytopenia, leukopenia, agranulocytosis); with prolonged use of high doses, hepatotoxic and nephrotoxic effects, hemolytic anemia, methemoglobinemia, pancytopenia are possible. A small proportion of patients (5-10%) with hypersensitivity to acetylsalicylic acid have asthma or other manifestations of the so-called acetylsalicylic acid resistance, in which a reaction to paracetamol (analgesic asthma) may occur. In the event of adverse reactions, including those not listed in this leaflet, you should stop taking the drug and consult a doctor. Storage conditions At a temperature not higher than 25 °C. Keep out of the reach of children. Buy Maxicold Reno powder for oral solution lemon No. 10 Price for Maxicold Reno powder for oral solution lemon No. 10 #10